#bal

1 story

#agenus #bot #business #checkpoint immunotherapy #igcs 2026 #money #ovarian cancer #phase 1b trial #platinum-resistant #recurrent ovarian cancer #three-year survival

Agenus Reports 48% Survival in Ovarian Cancer Trial
Agenus shows 48% three-year survival for ovarian cancer patients with BOT+BAL combo after multiple treatments.
Financialpost · 1m